Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

, ALNY

Alnylam

$70.30

1.73 (2.52%)

17:26
10/05/16
10/05
17:26
10/05/16
17:26

Ionis Pharmaceuticals down 5.2% after Alnylam drug development halt

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

ALNY

Alnylam

$70.30

1.73 (2.52%)

  • 07

    Oct

  • 14

    Oct

  • 06

    Nov

IONS Ionis Pharmaceuticals
$36.38

0.72 (2.02%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
JANY
09/28/16
INITIATION
Target $47
JANY
Buy
Ionis Pharmaceuticals initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Ionis Pharmaceuticals with a Buy and a $47 fair value estimate. Buchanan believes the late stage pipeline, including wholly-owned volanesorsen, and the base technology can add meaningful value to Ionis. 1H 2017 is particularly rich with 3 phase 3 readouts, with potential for another early, interim look at SMA.
10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.
ALNY Alnylam
$70.30

1.73 (2.52%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/15/16
09/15/16
INITIATION
Target $82

Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

12:17
01/16/18
01/16
12:17
01/16/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
01/16/18
01/16
12:16
01/16/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOV

National Oilwell

$38.90

-0.24 (-0.61%)

12:15
01/16/18
01/16
12:15
01/16/18
12:15
Options
National Oilwell put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

DPW

DPW Holdings

$2.41

-0.325 (-11.90%)

12:12
01/16/18
01/16
12:12
01/16/18
12:12
Hot Stocks
DPW Holdings falls almost 12% after announcing conversion of notes »

Sandstone Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBOW

SilverBow Resources

$31.88

-0.9386 (-2.86%)

12:10
01/16/18
01/16
12:10
01/16/18
12:10
Conference/Events
SilverBow Resources management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCEHY

Tencent

$56.92

1.565 (2.83%)

12:07
01/16/18
01/16
12:07
01/16/18
12:07
Hot Stocks
LEGO Group, Tencent form partnership in China »

The LEGO Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$101.32

0.35 (0.35%)

12:06
01/16/18
01/16
12:06
01/16/18
12:06
Hot Stocks
American Express reports December net write-off rate 2.0% vs. 1.9% last month »

Reports December 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

BX

Blackstone

$35.81

0.42 (1.19%)

12:05
01/16/18
01/16
12:05
01/16/18
12:05
Options
Blackstone call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

ICBK

County Bancorp

$30.16

0.38 (1.28%)

, MTW

Manitowoc

$40.09

0.73 (1.85%)

12:04
01/16/18
01/16
12:04
01/16/18
12:04
Hot Stocks
ICB to purchase Manitowoc Company headquarters »

Investors Community Bank,…

ICBK

County Bancorp

$30.16

0.38 (1.28%)

MTW

Manitowoc

$40.09

0.73 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$31.78

0.405 (1.29%)

12:02
01/16/18
01/16
12:02
01/16/18
12:02
Hot Stocks
Roche launches CE-marked VENTANA MMR IHC Panel »

Roche announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 23

    Feb

NSRGY

Nestle

$85.10

0.58 (0.69%)

12:02
01/16/18
01/16
12:02
01/16/18
12:02
Hot Stocks
Nestle agrees to sell U.S. confectionery business to Ferrero »

Nestle announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$54.16

-0.38 (-0.70%)

12:00
01/16/18
01/16
12:00
01/16/18
12:00
Periodicals
Hess to cut hundreds of jobs as it battles activist shareholder, Reuters says »

Hess plans to lay off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CECE

CECO Environmental

$5.22

-0.07 (-1.32%)

12:00
01/16/18
01/16
12:00
01/16/18
12:00
Hot Stocks
CECO Environmental reports award of 'large contract' to energy business »

CECO Environmental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

INFO

IHS Markit

$47.85

0.39 (0.82%)

11:55
01/16/18
01/16
11:55
01/16/18
11:55
Conference/Events
IHS Markit management to meet with RBC Capital »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

GSK

GlaxoSmithKline

$37.74

0.24 (0.64%)

11:54
01/16/18
01/16
11:54
01/16/18
11:54
Upgrade
GlaxoSmithKline rating change  »

GlaxoSmithKline upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 25

    Mar

GSK

GlaxoSmithKline

$37.76

0.2646 (0.71%)

11:51
01/16/18
01/16
11:51
01/16/18
11:51
Upgrade
GlaxoSmithKline rating change  »

GlaxoSmithKline upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 25

    Mar

SPY

SPDR S&P 500 ETF Trust

$278.99

1.07 (0.39%)

, SPX

S&P 500

11:50
01/16/18
01/16
11:50
01/16/18
11:50
Periodicals
Steve Bannon subpoenaed before grand jury by Mueller, NY Time says »

Special counsel Robert…

SPY

SPDR S&P 500 ETF Trust

$278.99

1.07 (0.39%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$11.67

0.1978 (1.72%)

11:50
01/16/18
01/16
11:50
01/16/18
11:50
Options
Large spreads in Petrobras as shares reach 52-week highs »

Large spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$62.38

3.72 (6.34%)

11:45
01/16/18
01/16
11:45
01/16/18
11:45
Options
Merck call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 02

    Feb

  • 08

    Feb

  • 25

    Mar

  • 03

    Apr

  • 23

    Oct

11:45
01/16/18
01/16
11:45
01/16/18
11:45
General news
Treasury's $90 B bill auction were mixed, with the 3-month outperforming »

Treasury's $90 B…

TTMI

TTM Technologies

$17.39

0.59 (3.51%)

11:45
01/16/18
01/16
11:45
01/16/18
11:45
Conference/Events
TTM Technologies management to meet with SunTrust »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

11:40
01/16/18
01/16
11:40
01/16/18
11:40
General news
U.S. VIX equity volatility is up nearly 10% »

U.S. VIX equity…

LPI

Laredo Petroleum

$11.09

0.015 (0.14%)

11:36
01/16/18
01/16
11:36
01/16/18
11:36
Initiation
Laredo Petroleum initiated  »

Laredo Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
01/16/18
01/16
11:35
01/16/18
11:35
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

11:34
01/16/18
01/16
11:34
01/16/18
11:34
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.